Antibacterial effects of antiretrovirals, potential implications for microbiome studies in HIV

Antiviral Therapy

Volumn 23, Issue 1, 2018, Pages 91-94

  Shilaih, Mohaned ^a,b   Angst, Daniel C ^c   Marzel, Alex ^a,b   Bonhoeffer, Sebastian ^c   Günthard, Huldrych F ^a,b   Kouyos, Roger D ^a,b  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY OF ZURICH   (Switzerland)

^c ETH ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPICILLIN; AMPRENAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR; CHLORAMPHENICOL; CIPROFLOXACIN; DARUNAVIR; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; ETRAVIRINE; INDINAVIR; KANAMYCIN; LAMIVUDINE; LOPINAVIR; MARAVIROC; NELFINAVIR; NEVIRAPINE; RALTEGRAVIR; RILPIVIRINE; RITONAVIR; SAQUINAVIR; STAVUDINE; TENOFOVIR; TENOFOVIR DISOPROXIL; TIPRANAVIR; UNINDEXED DRUG; ZALCITABINE; ZIDOVUDINE; ANTIINFECTIVE AGENT;

ANTIBACTERIAL ACTIVITY; ARTICLE; BACILLUS SUBTILIS; BACTERIAL GROWTH; BROTH DILUTION; COHORT ANALYSIS; COMMENSAL; CONTROLLED STUDY; DRUG EFFECT; ESCHERICHIA COLI; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; GROWTH INHIBITION; HUMAN IMMUNODEFICIENCY VIRUS; IN VITRO STUDY; MICROBIOME; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRESCRIPTION; PRIORITY JOURNAL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MICROFLORA; VIROLOGY; VIRUS LOAD;

ANTI-BACTERIAL AGENTS; ANTI-RETROVIRAL AGENTS; ESCHERICHIA COLI; HIV; HIV INFECTIONS; HUMANS; MICROBIAL SENSITIVITY TESTS; MICROBIOTA; VIRAL LOAD;

EID: 85036654612     PISSN: 13596535     EISSN: 20402058     Source Type: Journal    
DOI: 10.3851/IMP3173     Document Type: Article

References (20)

1. Nakagawa F, May M, Phillips A. Life expectancy living with HIV: Recent estimates and future implications. Curr Opin Infect Dis 2013; 26:17-25.
2. Li SX, Armstrong AJS, Neff CP, Shaffer M, Lozupone CA, Palmer BE. Complexities of gut microbiome dysbiosis in the context of HIV infection and antiretroviral therapy. Clin Pharmacol Ther 2016; 99:600-611.
3. Vujkovic-Cvijin I, Dunham RM, Iwai S, et al. Dysbiosis of the gut microbiota is associated with HIV disease progression and tryptophan catabolism. Sci Transl Med 2013; 5:193ra91.
4. Mutlu EA, Keshavarzian A, Losurdo J, et al. A compositional look at the human gastrointestinal microbiome and immune activation parameters in HIV infected subjects. PLoS Pathog 2014; 10:e1003829.
5. Yu G, Fadrosh D, Ma B, Ravel J, Goedert JJ. Anal microbiota profiles in HIV-positive and HIV-negative MSM. AIDS 2014; 28:753-760.
6. Noguera-Julian M, Rocafort M, Guillén Y, et al. Gut microbiota linked to sexual preference and HIV infection. EBio Medicine 2016; 5:135-146.
7. Elwell LP, Ferone R, Freeman GA, et al. Antibacterial activity and mechanism of action of 3′-Azido-3′-deoxythymidine (BW A509U). Antimicrob Agents Chemother 1987; 31:274-280.
8. Shilaih M, Marzel A, Scherrer AU, et al. Dually active HIV/HBV antiretrovirals protect against incident hepatitis B infections: potential for prophylaxis. J Infect Dis 2016; 214:599-606.
9. Mastrolorenzo A, Rusconi S, Scozzafava A, Barbaro G, Supuran C. Inhibitors of HIV-1 protease: current state of the art 10 years after their introduction. From antiretroviral drugs to antifungal, antibacterial and antitumor agents based on aspartic protease inhibitors. Curr Med Chem 2007; 14:2734-2748.
10. Forslund K, Hildebrand F, Nielsen T, et al. Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota. Nature 2015; 528:262-266.
11. Mäkivuokko H, Tiihonen K, Tynkkynen S, Paulin L, Rautonen N. The effect of age and non-steroidal antiinflammatory drugs on human intestinal microbiota composition. Br J Nutr 2010; 103:227-234.
12. Fantin B, Duval X, Massias L, et al. Ciprofloxacin dosage and emergence of resistance in human commensal bacteria. J Infect Dis 2009; 200:390-398.
13. Schoeni-Affolter F, Ledergerber B, Rickenbach M, et al. Cohort profile: The Swiss HIV Cohort study. Int J Epidemiol 2010; 39:1179-1189.
14. World Health Organization UNAIDS. Antiretroviral medicines in low-And middle-income countries: forecasts of global and regional demand for 2013-2016. 2014: v, 41. (Accessed 20 April 2016.) Available from http://apps.who.int/iris/handle/10665/111626.
15. Oswald S, Meyer zu Schwabedissen HE, Nassif A, et al. Impact of efavirenz on intestinal metabolism and transport: insights from an interaction study with ezetimibe in healthy volunteers. Clin Pharmacol Ther 2012; 91:506-513.
16. Thompson CG, Bokhart MT, Sykes C, et al. Mass spectrometry imaging reveals heterogeneous efavirenz distribution within putative HIV reservoirs. Antimicrob Agents Chemother 2015; 59:2944-2948.
17. Vrouenraets SME, Wit FWNM, van Tongeren J, Lange JMA. Efavirenz: A review. Expert Opin Pharmacother 2007; 8:851-871.
18. Camponeschi G, Fast J, Gauval M, et al. An overview of the antiretroviral market. Curr Opin HIV AIDS 2013; 8:535-543.
19. Kuster H, Vogt M, Joos B, Nadai V, Luthy R. A method for the quantification of intracellular zidovudine nucleotides. J Infect Dis 1991; 164:773-776.
20. Bazzoli C, Jullien V, Le Tiec C, Rey E, Mentré F, Taburet A-M. Intracellular pharmacokinetics of antiretroviral drugs in HIV-infected patients, and their correlation with drug action. Clin Pharmacokinet 2010; 49:17-45.